Outlook Therapeutics, Inc. (OTLK): restructuring charge — Outlook Therapeutics cuts workforce by 23% (5 employees) to preserve capital

Outlook Therapeutics, Inc.

Board approved reduction of 5 employees (~23% of headcount) on Dec 10; effective Dec 13.
Estimated restructuring charges of ~$0.3 million for severance, benefits, and related costs.
Majority of cash payments expected to be substantially complete by end of Q3 2025.
Severance contingent on release of claims; includes COBRA premiums for specified period.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Outlook Therapeutics, Inc. announced a restructuring with charges of approximately $ 0.3 million (5 people, or approximately 23% of the Company’s existing headcount).

Type: restructuring
Charge: approximately $ 0.3 million
Headcount: 5 people, or approximately 23% of the Company’s existing headcount

Exact text from the filing

eligibility for severance benefits is contingent upon execution of a general release of claims against the Company. The Company estimates that it will incur approximately $ 0.3 million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance and notice period payments, benefits and

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-128901

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.